IFNAR1 and infection: Thus, intending to use a model more representative of human CHIKV infection, we treated mice with a low dose (0.1 mg) of type I IFN receptor (IFNAR) antagonizing antibody MAR1–5A3 (herein referred to as MAR1) the day before infection.